anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
In vitro fertilization (IVF) involves a highly complex series of events leading to the creation of an embryo. The transfer of that embryo, the final step in the process, is seen as a critical moment at the culmination of this incredibly intricate process. The technique of the embryo transfer (ET) has undergone a slow evolution, but for many physicians, this step remains relatively consistent throughout years of practice. While the procedure itself is relatively short, physicians often have specific preferences for each of the steps involved, either supported by evidence, learned from mentors or guided by experience and individual success. As such, ET success rates are a statistic that generates significant pride among physicians and are often tracked by clinics as a quality control metric. Interestingly, there are significant outcome differences between physicians.

Numerous techniques and practices employed during ET have been studied. For some, the evidence is robust, while for others, it is very limited. Some practices and techniques were found to improve ET success, such as: abdominal US guidance, removal of cervical mucus, use of a soft catheter, and placement of the embryo at a distance of more than 10 mm from the uterine fundus. For other aspects of ET there is no sufficient evidence to decide on the preferred practice. These include the optimal length of the procedure and rotation of the catheter during withdrawal. Good-quality randomized clinical trials are much needed in order to decide on the best practice. For example, there was previously a concern that the use of powdered gloves during ET might be toxic to the embryos. However, a single RCT (n=712) has shown that using powdered gloves resulted in similar pregnancy rates compared to unpowdered gloves.

Lubrication gels are widely used in numerous gynecologic procedures in order to ease the insertion of speculum and visualize the cervix. It was shown that applying lubricating gels significantly decreases patient pain during vaginal speculum examination. While many fertility specialists use lubrication gels to insert the speculum during ET, others are strongly reluctant to use gels due to concern that they might have a detrimental effect on embryos and ET success. Similar concern was prevalent regarding the use of lubrication gel during Pap-smear for detection of cervical dysplasia. However, several studies have shown that the use of small amount of water-soluble gel does not change cervical cytology. Lubrication gels might have deleterious effect on sperm motility. However, there wasn't any study examining the effect of lubricant gel on ET success.

The investigators hypothesize that using a lubrication gel will not reduce the live birth rate per transfer, but decrease patient pain during procedure.
At study entry and Months 1 and 3, participants will receive HIV-MAG vaccine admixed with 1500 mcg of the IL-12 pDNA adjuvant divided into two 0.9 mL IM injections administered in both the left and right deltoids using the Ichor Medical Systems TDS EP device. At Month 6, they will receive the VSV HIV gag vaccine by IM injection in both the left and right deltoids.
The invention discloses application of miR-425 in tumor diagnosis, treatment and prognosis. Multiple biological characteristics of tumor including apoptosis, proliferation, drug susceptibility and the like disclosed by the invention are closely related to the expression quantity of miR-425. MiR-425 antagonist antimiR-425 can be used for significantly inhibiting proliferation of multiple types of tumor cells and the tumorigenic ability of the tumor cells in a nude mouse, and enhancing the tumor treatment capacity of chemotherapy drug cisplatin and the like in the nude mouse. The invention discloses a kit for tumor assisted diagnosis and patient survival prognosis, and the kit contains a primer sequence for the quantitative determination of miR-425; the invention also discloses a pharmaceutical composition for treating tumor, wherein the composition contains the miR-425 antagonist antimiR-425. The invention provides a novel method for assisted diagnosis and prognosis diagnosis of cancer. The invention discovers that the antimiR-425 has high clinical application value in the preparation of a tumor-treating medicine, and particularly provides a novel medicine and a treatment method for the effective treatment of lung cancer and liver cancer.
An azaazulene compound is provided. The azaazulene compound has formula (I) shown below. Each variable in formula (I) is defined in the specification. The compound can be used to treat cancer. The invention also provides a method for treating cancer. The method includes administering to a subject in need thereof an effective amount of one or more azaazulene compounds of formula (I).
This invention relates to novel multibinding compounds that bind to angiotensin (AT) receptors and modulate their activity. The compounds of this invention comprise 2-10 AT receptor ligands covalently connected by a linker or linkers, wherein the ligands in their monovalent (i.e., unlinked) state bind to one or more types of AT receptors. The manner of linking the ligands together is such that the multibinding agents thus formed demonstrate an increased biologic and/or therapeutic effect as compared to the same number of unlinked ligands made available for binding to AT receptors. The invention also relates to methods of using such compounds and to methods of preparing them. The compounds of this invention are particularly useful for treating diseases and conditions of mammals that are mediated by AT receptors. Accordingly, this invention also relates to pharmaceutical compositions comprising a pharmaceutically acceptable excipient and an effective amount of a compound of this invention.
The present invention provides use of epidermal growth factor in preparing a medicament for treating interstitial cystitis. According to the present invention, epidermal growth factor (EGF) can be used to establish an interstitial cystitis therapeutic agent. The medicament is a pharmaceutical composition comprising an active agent, an auxiliary agent, a dispersant, a wetting agent, and/or a suspending agent. The carrier of epidermal growth factor is water, a colloid, hyaluronic acid, a natural oil, and/or glucose. The medicament can be used for reducing the severity of pollakiuria, restoring bladder elasticity, reducing risks of bladder inflammation, and improving the anti-oxidation capacity in the bladder tissue. The present invention proposes novel use of epidermal growth factor for treating interstitial cystitis and repairing bladder mucosa.
PURPOSE:A liquid cosmetic useful especially as a pen type cosmetic tool, comprising pigment, a dispersant consisting of a copolymer of a hydrophobic unsaturated monomer and a hydrophilic unsaturated monomer, propylene glycol, glycerin, etc., as essential components. CONSTITUTION:A liquid cosmetic material consisting (A) 0.5-20wt% pigment, (B) 0.5-5pts.wt. (based on 10pts.wt. pigment) dispersant consisting of a copolymer of a hydrophobic unsaturated monomer and a hydrophilic unsaturated monomer and a salt thereof (e.g. styrene-acrylic acid copolymer) and (C) 2-30wt% propylene glycol, 1,3-butylene glycol, glycerin or polyethylene glycol alone or a mixture thereof as a humectant and an antifreezing agent. The cosmetic has improved delivery from pen point, low clogging of pen point, improved line drawing and coating performance especially useful as a pen type cosmetic tool such as eye liner, mascara, etc.
Cangpo Liujun Prescription composition: Rhizoma atractylodis 15g, Magnolia officinalis 12g, Tangerine peel 15g, Pinellia pinellia 12g, Codonopsis ginseng 15g, Rhizoma atractylodis macrocephalae 15g, Poria cocos 15g, Honey-fried licorice root 6g. It was taken during and between the treatments, in the morning and in the evening, 200ml each time, for 3 courses, and 1 course was 28 days.
The invention provides a fraction containing the active ingredient contained in plant worms. The invention also provides a means efficacious in immunopotentiation, an effective means of preventing or treating cancer and a composition useful in producing health foods. It is intended to provide a precipitation fraction obtained by extracting plant worms mycelium with hot water and adding ethanol to the thus obtained extract. It is also intended to provide a composition for oral intake which contains the above precipitation fraction. It is further intended to provide foods, drinks, immunopotentiators, anticancer agents and so on containing the above composition for oral intake which are characterized by having an anticancer effect, an effect of preventing cancer or an immunopotentiation effect. It is furthermore intended to provide a method of effectively producing the above-described composition for oral intake.
TCHP (Docetaxel, Carboplatin, Trastuzumab, Pertuzumab, Pegfilgrastim ) institutional practice is to titrate the infusion rate on the initial Paclitaxel dose (40 ml/hr x 5 min, then 80 ml/hr x 5 min, then 120 ml/hr x 10 min, then 200 ml/hr). Subsequent Paclitaxel doses are given over 1 hour.
Intestinal failure-associated liver disease (IFALD) is a serious life-limiting complication that can occur throughout the clinical course of intestinal failure and its management by parenteral nutrition (PN). Despite this, there is a lack of a standardized definition for IFALD, which makes this insidious condition increasingly difficult to screen and diagnose in clinical practice. Attenuating the progression of liver disease before the onset of liver failure is key to improving morbidity and mortality in these patients. This requires timely detection and promptly addressing reversible factors. Although there are various noninvasive tools available to the clinician to detect early fibrosis or cirrhosis in various chronic liver disease states, these have not been validated in the patient population with IFALD. Such tools include biochemical composite scoring systems for fibrosis, transient elastography, and dynamic liver function tests. This review article aims to highlight the existing real need for an accurate, reproducible method to detect IFALD in its early stages. In addition, we also explore the role PN plays in the pathogenesis of this complex multifactorial condition. Various aspects of PN administration have been implicated in the etiology of IFALD, including the composition of the lipid component, nutrient excess and deficiency, and infusion timing. We aim to highlight the clinical relevance of these PN-associated factors in the development of IFALD and how these can be managed to mitigate the progression of IFALD.
The invention discloses a method for utilizing the macroporous adsorption resin to prepare the total saponins of the herba centellae. The operation procedures of the method is carried out as follows, 1) aqueous ethanol solution is added into the dry herba centellae for immersion and extraction, the extracting solution is mixed and removed ethanol by the vacuum concentraction, and the concentrated solution is diluted by water and filtered to obtain the aqueous total saponins of the herba centellae solution. 2), the pretreated macroporous adsorption resin is filled into the chromatography column. 3), the aqueous total saponins solution is introduced to flow through the resin column till penetration of the total saponins in the effluent. 4), the resin column is washed by water and eluted by the organic solvent-water mixture, the eluent is mixed after the thin layer chromatographic analysis, then is concentrated, crystallized and vacuum dried to obtain the total saponins product. 5), the resin column is washed and regenerated by the organic solvent-water mixture and water for reuse. The invention has the advantages of the higher absorption capacity of the total saponins of the herba centellae by the macroporous adsorption resin, easy desorption, higher recovery rate and higher contents of the total saponins of the herba centellae, simple method, strong operability, higher yield of the total saponins of the herba centellae and lower cost.
This study examined the sensory profile of three groups of children (those with visual impairment, typical development or autism spectrum disorder) aged 3 to 12. The principal aim was to find out whether the Sensory Profile (SP) of children with visual impairment was a good predictor of behaviors typical of ASD. The data was collected through a sensory profile filled out by parents of 37 visually impaired children, 30 with autism spectrum disorder (ASD) and 42 with typical development (TD). To assess the risk of ASD, the Social Communication Questionnaire (SCQ) was also administered. The results indicate that children with visual impairment are at increased risk of exhibiting signs of ASD, and that the sensory profile is a good predictor of risk of autistic signs in children with visual impairment. This study provides for the first time strong evidence for the need to systematically assess the sensory profile in children with visual impairment.
Expansion cohort of DF1001 in combination with nab-paclitaxel after evaluation for safety in the Combination Therapy with DF1001 and nab-paclitaxel Dose Escalation arm. Additional pharmacokinetic (PK) and pharmacodynamic (PD) samples included in this arm.
These patients must be willing to be followed up for 1 year and agreeing to give the informed consent. Recruitment period will take up to three months. Follow up period will be conducted at the end of first, second and third trimester and three months after giving birth.
Human papillomavirus (HPV)-related multiphenotypic sinonasal carcinoma (HMSC) is a recently described neoplasm entity that presents only in the sinonasal tract. Histologically, it displays features of both a surface-derived carcinoma and a salivary gland carcinoma, and is associated with high-risk HPV, specifically HPV type 33. Whereas majority of the cases display high-grade histologic features, HMSC paradoxically behaves in a relatively indolent fashion. It is important and meaningful to distinguish HMSC from other histopathologic mimickers as the clinical features and management are distinctive. A 64-year-old woman presented having intermittent left-side epistaxis and progressive nasal obstruction. A well-defined, solitary, friable mass with an irregular surface that easily bled upon contact was found in the posterior part of the left nasal cavity. Endoscopic excision of the tumor which was originated from left nasal septum was done and the tumor was confirmed as HMSC. After surgery, definitive radiotherapy was performed in 28 fractions. HMSC is a histopathological type that has been rarely reported so that we report this case with literature review.
BACKGROUND: Acute decompensated heart failure (ADHF) presents a significant global health challenge, with high morbidity, mortality, and healthcare costs. The current therapeutic options for ADHF are limited. Ivabradine, a selective inhibitor of hyperpolarization-activated cyclic nucleotide-gated (HCN) channels, has emerged as a potential therapy for ADHF by reducing the heart rate (HR) without negatively affecting myocardial contractility. However, the evidence regarding the efficacy and safety of ivabradine in patients with ADHF is limited and inconsistent. This meta-analysis aimed to evaluate the efficacy and safety of ivabradine for ADHF based on observational studies.
METHODS: A systematic literature search was conducted following PRISMA guidelines to identify relevant observational studies comparing ivabradine with placebo in adult patients with ADHF. Data were pooled using a random-effects model, and heterogeneity was assessed. The risk of bias was evaluated using the Newcastle-Ottawa Scale.
RESULTS: Four observational studies comprising a total of 12034 patients. Meta-analysis revealed that ivabradine significantly reduced all-cause mortality (RR: 0.66, 95 % CI: 0.49-0.89, p < 0.01) and resting HR (MD: -12.54, 95 % CI: -21.66-3.42, p < 0.01) compared to placebo. However, no significant differences were observed in cardiovascular mortality, hospital readmission for all causes, changes in LVEF, or changes in LVEDD. Sensitivity and publication bias assessments were conducted for each outcome.
CONCLUSION: Ivabradine may be beneficial for reducing mortality and HR in patients with ADHF. However, its impact on other clinical outcomes such as cardiovascular mortality, hospital readmission, and cardiac function remains inconclusive. Further research, particularly well-designed RCTs with larger sample sizes and longer follow-up durations, are warranted.
Prediabetes is characterized by a cluster of glycemic parameters higher than normal but below the threshold of type 2 diabetes mellitus (T2DM). In recent years, phytochemical-rich plant extracts have gained popularity as therapeutic agents for metabolic disorders. This study investigated the effects of papaya leaf (PL) juice supplementation on blood glucose levels in diet-induced obese and prediabetic adult mice. B65JL F1 mice (n = 20) at 12-14 months old were fed a high fat/sugar diet (HFHS) for 120 days. Mice were switched to restricted rodent chow of 3 g feed/30 g body weight/day, supplemented with 3 g/100 mL PL juice for 30 days. HFHS diet remarkably increased fasting plasma glucose levels from 114 ± 6.54 mg/dL to 192.7 ± 10.1 mg/dL and body weight from 32.5 ± 1.6 to 50.3 ± 4.1 g. HFHS diet results in hyperglycemia, insulin resistance, hyperlipidemia, and liver steatosis. The combination of PL juice and restricted diet significantly reduced body weight and fasting blood glucose levels to 43.75 ± 1.4 g and 126.25 ± 3.2 mg/dl, respectively. Moreover, PL juice with a restricted diet significantly improved lipid profile: cholesterol from 204 to 150 mg/dL, LDL-c from 110.4 to 50 mg/dL, and triglyceride from 93.7 to 60 mg/dL. Additionally, PL juice combined with a restricted diet significantly reduced adiposity, reversed fatty liver, and restored skeletal muscle Glut4 and phosphorylated (p-AKT (ser473). This study demonstrated that supplementation of PL juice with a restricted diet was more effective than a restricted diet alone in reversing major symptoms related to prediabetic and obesity conditions.
PCT No. PCT/GB95/00707 Sec. 371 Date Nov. 13, 1996 Sec. 102(e) Date Nov. 13, 1996 PCT Filed Mar. 29, 1995 PCT Pub. No. WO95/27066 PCT Pub. Date Oct. 12, 1995The invention relates to methods for determining a predisposition for and diagnosing the existence of a degenerative disease or a cancer and also products and processes for treating and obtaining treatments for such a degenerative disease or a cancer. The invention has particular application in the use of information concerning the elucidation of DNA and amino acid sequence structure relating to human and mouse ubiquitin conjugating enzymes.
Participants will then be invited to participate in an 8-week, group-based acupuncture treatment intervention delivered by a licensed acupuncturist. The group will meet weekly for 8 consecutive weeks, each session lasting about 75 minutes.
A method for the identification of unique fibronectin-targeting peptides derived from the tryptic digestion of purified gelatin is described. Two unique peptides are isolated and shown to have higher affinities for fibronectin than the gelatin alone. The peptides are stabilized and delivered by covalently bonding to the phosphatidylethanolamine existing naturally in phospholipid-stabilized triglyceride emulsions currently employed clinically as injectable nutritional emulsions. Unexpectedly, we discovered that the peptides could be coupled to emulsion droplets in situ. One of the systems identified as the 12-mer Peptide I linked to the phosphatidylethanolamine through its N-terminus (PIN-E), is shown to retain the fibronectin-affinity of the starting material and to inhibit the spreading activity of baby hamster kidney cells, a well-recognized in vitro model of metastatic tumor spreading activity. This particular system is stable at refrigerator temperature for at least a month but demonstrates some decoupling of the peptide and aggregation of the emulsion droplets in the presence of rabbit serum at 37 °C after two days storage. It is anticipated that these systems will have utility by passively blocking metastatic processes that involve fibronection. In addition, they would have advantages as drug delivery systems specifically targeting fibronectin-enriched surfaces, especially for hydrophobic drugs such as paclitaxel (Taxol®).
OBJECTIVES: Streptococcal toxic shock syndrome (STSS) is caused by group A Streptococcus (GAS; Streptococcus pyogenes) strains. In Japan, the number of STSS cases has decreased; however, the underlying reason remains unclear. Moreover, information on distribution and prevalence of specific emm types in STSS cases is scarce. Hence, we investigated the reason for the decreased number of STSS cases in Japan.
METHODS: We genotyped emm of 526 GAS isolates obtained from 526 patients with STSS between 2019 and 2022. The distributions of emm types in each year were compared.
RESULTS: The emm1 type was predominant, with the highest proportion in 2019, which decreased after 2020 following the onset of the coronavirus disease 2019 (COVID-19) pandemic. Strains isolated during the pandemic correlated with strains associated with skin infection, whereas those isolated during the prepandemic period correlated with strains associated with both throat and skin infections. The decrease in the annual number of STSS cases during the COVID-19 pandemic could be due to a decreased proportion of strains associated with pharyngeal infections.
CONCLUSIONS: Potential associations between pandemic and STSS numbers with respect to public health measures, such as wearing masks and changes in healthcare-seeking behavior, may have affected the number of GAS-induced infections.
Pregnancy Category C. 

There are no adequate and well-controlled studies in pregnant women. It is unknown whether PRANDIN can cause fetal harm when administered to a pregnant woman. PRANDIN should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. 

Repaglinide was not teratogenic in rats or rabbits at doses 40 times (rats) and approximately 0.8 times (rabbit) clinical exposure (on a mg/m2 basis) throughout pregnancy. Offspring of rat dams exposed to repaglinide at 15 times clinical exposure on a mg/m2 basis during days 17 to 22 of gestation and during lactation developed nonteratogenic skeletal deformities consisting of shortening, thickening, and bending of the humerus during the postnatal period. This effect was not seen at doses up to 2.5 times clinical exposure (on a mg/m2 basis) on days 1 to 22 of pregnancy or at higher doses given during days 1 to 16 of pregnancy. Relevant human exposure has not occurred to date and therefore the safety of PRANDIN administration throughout pregnancy or lactation cannot be established.